Moleculin Biotech Return On Equity vs. Current Valuation
| MBRX Stock | USD 2.73 0.10 3.53% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter (1.14) | Current Value (1.08) | Quarterly Volatility 0.89986877 |
For Moleculin Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Moleculin Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Moleculin Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Moleculin Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Moleculin Biotech over time as well as its relative position and ranking within its peers.
Moleculin |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.04) | Return On Assets (0.57) | Return On Equity (1.41) |
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moleculin Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Moleculin Biotech Current Valuation vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Moleculin Biotech's current stock value. Our valuation model uses many indicators to compare Moleculin Biotech value to that of its competitors to determine the firm's financial worth. Moleculin Biotech is rated below average in return on equity category among its peers. It is rated below average in current valuation category among its peers . At this time, Moleculin Biotech's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Moleculin Biotech's earnings, one of the primary drivers of an investment's value.Moleculin Current Valuation vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Moleculin Biotech |
| = | -1.41 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Moleculin Biotech |
| = | (819.83 K) |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Moleculin Current Valuation vs Competition
Moleculin Biotech is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 942.51 Million. Moleculin Biotech has negative current valuation of (819,827) having no influence on the industry.
Moleculin Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Moleculin Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Moleculin Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Moleculin Biotech's change in net profit over the period of time. It can combine multiple indicators of Moleculin Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -9 K | -8.6 K | |
| Interest Income | 1.2 M | 965.1 K | |
| Operating Income | -29.6 M | -28.1 M | |
| Net Loss | -26.3 M | -25 M | |
| Income Before Tax | -29.8 M | -28.3 M | |
| Total Other Income Expense Net | -138 K | -131.1 K | |
| Net Loss | -14.3 M | -15 M | |
| Net Loss | -29.8 M | -28.3 M | |
| Income Tax Expense | -1.5 M | -1.5 M | |
| Net Interest Income | 1.2 M | 1.3 M | |
| Non Operating Income Net Other | 2.7 M | 1.9 M | |
| Change To Netincome | -3.8 M | -3.6 M | |
| Net Loss | (15.07) | (15.82) | |
| Income Quality | 0.81 | 0.76 | |
| Net Income Per E B T | 1.09 | 0.92 |
Moleculin Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Moleculin Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Moleculin Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Moleculin Biotech's important profitability drivers and their relationship over time.
Use Moleculin Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Moleculin Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Moleculin Biotech will appreciate offsetting losses from the drop in the long position's value.Moleculin Biotech Pair Trading
Moleculin Biotech Pair Trading Analysis
The ability to find closely correlated positions to Moleculin Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Moleculin Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Moleculin Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Moleculin Biotech to buy it.
The correlation of Moleculin Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Moleculin Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Moleculin Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Moleculin Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Moleculin Biotech position
In addition to having Moleculin Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Synthetics Thematic Idea Now
Synthetics
Companies involved in production of silicon and other synthetic products . The Synthetics theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Synthetics Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.